GCP
YMAB

GSA Capital Partners’s Y-mAbs Therapeutics YMAB Stock Holding History

GSA Capital Partners’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-186,062
Closed -$839K – 2172
2025
Q2 		$839K Buy
186,062
+165,431
+802% +$744K 0.06% 572
2025
Q1 		$91K Buy
+20,631
New +$120K 0.01% 1513
2023
Q4 		– Sell
-137,299
Closed -$748K – 1996
2023
Q3 		$748K Buy
137,299
+92,765
+208% +$540K 0.06% 554
2023
Q2 		$302K Sell
44,534
-116,975
-72% -$877K 0.03% 1048
2023
Q1 		$809K Buy
161,509
+62,349
+63% +$255K 0.08% 433
2022
Q4 		$484K Buy
+99,160
New +$720K 0.06% 620
2022
Q1 		– Sell
-69,311
Closed -$1.12M – 1904
2021
Q4 		$1.12M Buy
+69,311
New +$1.48M 0.14% 155
2018
Q4 		– Sell
-10,000
Closed -$266K – 1792
2018
Q3 		$266K Buy
+10,000
New +$254K 0.01% 1377

Other funds holding YMAB

BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

GSA Capital Partners's YMAB Position: Q3 2025 in Review

GSA Capital Partners sold out of Y-mAbs Therapeutics (YMAB) in Q3 2025, closing a stake of 186,062 shares — an estimated $839K sold.

GSA Capital Partners first reported a position in YMAB in Q3 2018 and held it in 8 quarters. The position peaked at $1.12M in Q4 2021. 2 funds tracked by Wall St. Rank hold YMAB as of Q3 2025.

  • GSA Capital Partners reported no remaining Y-mAbs Therapeutics position as of Q3 2025 after selling out during the quarter.
  • GSA Capital Partners sold 186,062 Y-mAbs Therapeutics shares in Q3 2025, an estimated $839K.
  • GSA Capital Partners first reported a position in Y-mAbs Therapeutics in Q3 2018 and held it in 8 quarters.
  • GSA Capital Partners's Y-mAbs Therapeutics position peaked at $1.12M in Q4 2021.
  • 2 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q3 2025.

Based on GSA Capital Partners's 13F filing for Q3 2025, filed 7 Nov 2025.